Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

• Status: Recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Guthrie Clinic
• Treatments: Adenosine; Fentanyl; Ticagrelor

Criteria

Inclusion Criteria:

• Undergoing clinically indicated elective or non-elective PCI

• Able to swallow oral medications

Exclusion Criteria:

• Contraindications to ticagrelor or fentanyl (or other opiates)

• Pregnancy

• Any use of P2Y12 inhibitors within 14 days

• Known coagulation disorders

• Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular weight heparin)

• Platelet count < 100,000/mm3

• Impaired renal function (Estimated glomerular filtration < 45 ml/min/1.73 m2)

• Impaired hepatic function (Based on medical history)

• Prior or planned transcatheter aortic valve replacement